Oral treatments for outpatient COVID-19: Effectiveness and value

• DOI: 10.18553/jmcp.2022.28.8.903
• Publication Date: 2023-01-13T22:52:05Z
• Authors: Molly Beinfeld; Kai Yeung; Melanie D Whittin...; Rasheed Mohammed; Emily Nhan; Steven D Pearson
• Keywords: Anthem; Health plan

DISCLOSURES: Ms Beinfeld and Nahn Drs Whittington, Mohammed, Pearson report grants from Arnold Ventures, Kaiser Foundation Health Plan Inc., The Patrick Catherine Weldon Donaghue Medical Research Foundation, Blue Cross Shield of Massachusetts, Commonwealth during the conduct study; other America's Insurance Plans, Anthem, AbbVie, Alnylam, AstraZeneca, Biogen, CA, Cambia Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Care Service Corporation, Partners, Johnson & (Janssen), Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, United Healthcare, HealthFirst, Pfizer, Boehringer-Ingelheim, uniQure, Humana, Sun Life, Envolve Pharmacy Solutions, outside submitted work. Dr Yeung received a contract ICER to be an evidence author for COVID-19 outpatient treatments.